Clinicopathological, immunohistochemical, molecular-genetic and risk profiles of gastrointestinal stromal tumors in a cohort of Sudanese patients
- PMID: 37545902
- PMCID: PMC10398493
- DOI: 10.4314/ahs.v23i1.47
Clinicopathological, immunohistochemical, molecular-genetic and risk profiles of gastrointestinal stromal tumors in a cohort of Sudanese patients
Abstract
Background: Determining the risk of malignant behaviour and mutational status of gastrointestinal stromal tumours (GISTs) guide the management decision and allow optimal individualized patient treatment.
Objectives: To determine clinicopathological, immunohistochemical (IHC), risk and KIT mutational findings of GISTs in Sudanese patients.
Methods: Histological slides were reviewed, IHC for DOG-1 and CD117 performed and hotspot KIT mutations examined. The risk group was assigned using combined risk criteria.
Results: 21 of the 36 patients (58.3%) were males (mean age, 54.83 ±12.57; range, 26-71). Abdominal pain and mass were the most frequent symptoms. Mean tumor size (±SD) was 11.6(±5.82) cm. Either CD117, DOG1 or both were positive in all cases. Using risk criteria, 33.3% (n=12) were clinically malignant at presentation, 13.9% (n=5) high risk, 16.7% (n=6) intermediate, 27.8% (n=10) low risk and 2.8% (n=1) very low risk. Sixteen of 23 (70%) tested cases had KIT (14 exon 11 and two exon 9) mutations. Six tumors were wild type. Exon 11 deletions (p.I563-L576 del and p.V559-N566delinsD) significantly correlate with disease recurrence (p-value: 0.028).
Conclusions: Sudanese patients with GIST tend to present late. Nearly half of them correspond to the malignant/high-risk category. The frequency of KIT mutations (79.31%) is in line with the literature.
Keywords: DOG1; GIST; Gastrointestinal stromal tumour; Imatinib; KIT; genotyping; malignant behaviour; metastasis; risk assessment; risk stratification; tumour rupture.
© 2023 Husain NE et al.
Conflict of interest statement
Authors declare that they have any competing interests.
Figures

Similar articles
-
[Clinicopathological features and prognosis of gastrointestinal stromal tumors with KIT/PDGFRA gene "homozygous mutation": a multicenter retrospective cohort study].Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Sep 25;24(9):804-813. doi: 10.3760/cma.j.cn.441530-20210720-00293. Zhonghua Wei Chang Wai Ke Za Zhi. 2021. PMID: 34530562 Chinese.
-
[Differences in clinicopathological features, gene mutations, and prognosis between primary gastric and intestinal gastrointestinal stromal tumors in 1061 patients].Zhonghua Wei Chang Wai Ke Za Zhi. 2023 Apr 25;26(4):346-356. doi: 10.3760/cma.j.cn441530-20220531-00234. Zhonghua Wei Chang Wai Ke Za Zhi. 2023. PMID: 37072312 Chinese.
-
Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours.Scand J Gastroenterol. 2013 Sep;48(9):1055-65. doi: 10.3109/00365521.2013.816770. Epub 2013 Jul 17. Scand J Gastroenterol. 2013. PMID: 23862765
-
Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.Hum Pathol. 2017 Apr;62:206-214. doi: 10.1016/j.humpath.2017.01.005. Epub 2017 Feb 1. Hum Pathol. 2017. PMID: 28159677 Review.
-
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.Histopathology. 2008 Sep;53(3):245-66. doi: 10.1111/j.1365-2559.2008.02977.x. Epub 2008 Feb 28. Histopathology. 2008. PMID: 18312355 Review.
Cited by
-
Advancing gastrointestinal stromal tumor management: The role of imagomics features in precision risk assessment.World J Gastrointest Surg. 2024 Sep 27;16(9):2942-2952. doi: 10.4240/wjgs.v16.i9.2942. World J Gastrointest Surg. 2024. PMID: 39351558 Free PMC article.
-
Editor's choice: COVID-19 and other infections in Africa.Afr Health Sci. 2023 Mar;23(1):i-v. doi: 10.4314/ahs.v23i1.1. Afr Health Sci. 2023. PMID: 37545915 Free PMC article. No abstract available.
References
-
- Gupta SK, Rateria N. Gastrointestinal Stromal Tumors (GIST): an Overview. Indian Journal of Surgery. 2020:1–7. - PubMed
-
- Khoo CY, et al. Systematic review of current prognostication systems for primary gastrointestinal stromal tumors. European Journal of Surgical Oncology. 2018 - PubMed
-
- Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003;54(1):3–24. - PubMed
-
- Fletcher CD, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human pathology. 2002;33(5):459–465. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources